Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · IEX Real-Time Price · USD
56.41
+0.50 (0.89%)
At close: Jul 19, 2024, 4:00 PM
56.42
+0.01 (0.02%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Cytokinetics Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 78.25, with a low estimate of 50 and a high estimate of 106. The average target predicts an increase of 38.72% from the current stock price of 56.41.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 16 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 6 | 6 | 6 |
| Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Hold | 3 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 15 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $77 → $65 | Buy | Maintains | $77 → $65 | +15.23% | Jun 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +59.55% | Jun 17, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $122 → $92 | Strong Buy | Maintains | $122 → $92 | +63.09% | Jun 4, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $78 | Buy | Reiterates | $78 | +38.27% | May 31, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $86 → $70 | Strong Buy | Maintains | $86 → $70 | +24.09% | May 29, 2024 |
Financial Forecast
Revenue This Year
14.67M
from 7.53M
Increased by 94.78%
Revenue Next Year
84.29M
from 14.67M
Increased by 474.66%
EPS This Year
-4.61
from -5.45
EPS Next Year
-4.44
from -4.61
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 56.7M | 237.2M | 578.5M | 1.8B | 2.7B |
| Avg | 14.7M | 84.3M | 372.9M | 979.7M | 1.6B |
| Low | 784,000 | 4.9M | 218.5M | 405.1M | 707.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 653.0% | 1,517.2% | 586.3% | 377.9% | 174.2% |
| Avg | 94.8% | 474.7% | 342.4% | 162.7% | 67.1% |
| Low | -89.6% | -66.6% | 159.3% | 8.6% | -27.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.23 | -2.81 | -0.04 | 6.72 | 11.43 |
| Avg | -4.61 | -4.44 | -2.56 | 1.53 | 4.72 |
| Low | -5.02 | -5.96 | -5.78 | -0.80 | 2.09 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 649.0% |
| Avg | - | - | - | - | 209.2% |
| Low | - | - | - | - | 36.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.